Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · May 2017
Multicenter StudyProspective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases.
Serologic diagnosis of autoimmune blistering disease (AIBD) usually follows a sophisticated multistep algorithm. ⋯ The multivariant ELISA is a practical, highly standardized, and widely available novel diagnostic tool for the routine diagnosis of AIBD.
-
J. Am. Acad. Dermatol. · Jan 2016
Multicenter StudyA retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
There is a paucity of studies to substantiate whether the presence of a single mitosis justifies sentinel lymph node (SLN) biopsy (SLNB) in thin melanomas. ⋯ Mitotic rate does not have unequivocal utility in predicting SLNB status in thin melanomas. There is a significant interaction between mitotic rate and Breslow depth, such that the predictive value of mitotic rate on SLN positivity may be dependent on Breslow thickness.
-
J. Am. Acad. Dermatol. · Aug 2015
Multicenter Study Comparative StudyAdverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
Safety profiles of biologics for treatment of psoriasis are limited to data from randomized controlled trials. There is a need for comparative safety reports of biologics based on data from clinical practice. ⋯ Biologic agents for treatment of psoriasis are safe; AEs associated with withdrawal occurred in 4% of all administered biologic therapies. It does not appear that real-world patients encounter more AEs with biologics than patients in clinical trials.
-
J. Am. Acad. Dermatol. · Jul 2015
Randomized Controlled Trial Multicenter StudyApremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Apremilast works intracellularly to regulate inflammatory mediators. ⋯ Apremilast was effective in moderate to severe plaque psoriasis.